Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
This year’s most widely viewed stories focused on HIV cure and vaccine news, long-acting treatment and coexisting conditions.
Updated guidance is based on findings from the REPRIEVE trial, which showed pitavastatin reduced the risk of cardiovascular events by 35%.
NAFLD is associated with risk factors such as obesity and inflammatory biomarkers and with events including heart attacks and strokes.
NIH’s Carl Dieffenbach and Bill Kapogiannis interview experts about research presented at IAS 2023.
REPRIEVE trial finds pitavastatin reduced the risk for heart attack, stroke and other major cardiovascular events by 35%.
Large trial finds that pitavastatin lowered the risk for major cardiovascular events by 35%.
Baseline readings in the REPRIEVE study show sex and race differences in electrocardiograph outcomes.
The proportion without symptoms was higher than previously seen in many studies of both people with HIV and the general population.
Scientists are looking at whether blocking the receptor PCSK9 could reduce heart disease in people living with HIV.
The first data from the much anticipated REPRIEVE trial on statin medications for people with HIV are out.
An HIV-specific model underestimated the risk for heart attacks and other cardiovascular events.
White men and smokers are more likely to have arterial plaque despite low cardiovascular risk scores.
The REPRIEVE study, which is primarily looking at a statin’s effect on cardiovascular disease, is shedding light on many other mysteries.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.